Progress in Cancer Immunotherapy
This book provides readers an extensive overview of recent progress in basic and clinical research on cancer immunotherapy. Thanks to rapid advances in molecular biology and immunology, it has become increasingly evident that cancer growth is influen
- PDF / 3,354,396 Bytes
- 293 Pages / 439.42 x 683.15 pts Page_size
- 30 Downloads / 253 Views
Shuren Zhang Editor
Progress in Cancer Immunotherapy
Advances in Experimental Medicine and Biology
Volume 909
Editorial Board Irun R. Cohen, The Weizmann Institute of Science, Rehovot, Israel N.S. Abel Lajtha, Kline Institute for Psychiatric Research, Orangeburg, NY, USA John D. Lambris, University of Pennsylvania, Philadelphia, PA, USA Rodolfo Paoletti, University of Milan, Milan, Italy
More information about this series at: http://www.springer.com/series/5584
Shuren Zhang Editor
Progress in Cancer Immunotherapy
Editor Shuren Zhang Department of Immunology Cancer Hospital & Institute Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China
ISSN 0065-2598 ISSN 2214-8019 (electronic) Advances in Experimental Medicine and Biology ISBN 978-94-017-7553-3 ISBN 978-94-017-7555-7 (eBook) DOI 10.1007/978-94-017-7555-7 Library of Congress Control Number: 2016937714 © Springer Science+Business Media Dordrecht 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer Science+Business Media B.V. Dordrecht
Preface
The great success achieved by immune checkpoint inhibitors and CAR-T cells dismissed the doubt of efficacy of immunotherapy in the treatment of cancer over the past century. The treatments targeting immune negative regulators have verified the immune editing theory, which have been established at the turn of the century. Previously, immune surveillance theory provided the notion of how the immune system can recognize and kill tumors, but did not fully consider reciprocity in the interaction between the immune system and the tumor. Immune editing theory makes us aware of regulatory controls that promote the development of tumors. Targeting negative immune checkpoints (such as the use of anti-CTLA4 and antiPD-1 therapeutic antibodies), which are not against tumor targets, can elicit significant anti-tumor effects. This liberatio
Data Loading...
